BioCryst Pharma (BCRX) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 +0.45%
Revenue Growth %: +13.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +13.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $81 million versus the consensus estimate of $81.41 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Goldman starts Talen at buy, sees PJM power tightness boosting earnings
- Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
